GINDRAUX, Florelle, Nicola HOFMANN, Marta AGUDO-BARRIUSO, Mariastefania ANTICA, Pedro Silva COUTO, Marie DUBUS, Serhiy FOROSTYAK, Lenart GIRANDON, Roberto GRAMIGNOLI, Marcin JURGA, Sergio LIARTE, Ruta NAVAKAUSKIENE, Volodymyr SHABLII, Xavier LAFARGE a Francisco J NICOLAS. Perinatal derivatives application: Identifying possibilities for clinical use. Frontiers in bioengineering and biotechnology. Laussane: Frontiers Media S.A., 2022, roč. 10, October 2022, s. 1-20. ISSN 2296-4185. Dostupné z: https://dx.doi.org/10.3389/fbioe.2022.977590.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Perinatal derivatives application: Identifying possibilities for clinical use
Autoři GINDRAUX, Florelle (garant), Nicola HOFMANN, Marta AGUDO-BARRIUSO, Mariastefania ANTICA, Pedro Silva COUTO, Marie DUBUS, Serhiy FOROSTYAK (203 Česká republika, domácí), Lenart GIRANDON, Roberto GRAMIGNOLI, Marcin JURGA, Sergio LIARTE, Ruta NAVAKAUSKIENE, Volodymyr SHABLII, Xavier LAFARGE a Francisco J NICOLAS.
Vydání Frontiers in bioengineering and biotechnology, Laussane, Frontiers Media S.A. 2022, 2296-4185.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 10601 Cell biology
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.700
Kód RIV RIV/00216224:14110/22:00128445
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3389/fbioe.2022.977590
UT WoS 000876508500001
Klíčová slova anglicky clinical trials; perinatal derivatives; ICD-10=international classification of diseases; questionnaire for PnD use in human conditions; amniotic membrane
Štítky 14110229, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 31. 1. 2023 13:22.
Anotace
Perinatal derivatives are drawing growing interest among the scientific community as an unrestricted source of multipotent stromal cells, stem cells, cellular soluble mediators, and biological matrices. They are useful for the treatment of diseases that currently have limited or no effective therapeutic options by means of developing regenerative approaches. In this paper, to generate a complete view of the state of the art, a comprehensive 10-years compilation of clinical-trial data with the common denominator of PnD usage has been discussed, including commercialized products. A set of criteria was delineated to challenge the 10-years compilation of clinical trials data. We focused our attention on several aspects including, but not limited to, treated disorders, minimal or substantial manipulation, route of administration, dosage, and frequency of application. Interestingly, a clear correlation of PnD products was observed within conditions, way of administration or dosage, suggesting there is a consolidated clinical practice approach for the use of PnD in medicine. No regulatory aspects could be read from the database since this information is not mandatory for registration. The database will be publicly available for consultation. In summary, the main aims of this position paper are to show possibilities for clinical application of PnD and propose an approach for clinical trial preparation and registration in a uniform and standardized way. For this purpose, a questionnaire was created compiling different sections that are relevant when starting a new clinical trial using PnD. More importantly, we want to bring the attention of the medical community to the perinatal products as a consolidated and efficient alternative for their use as a new standard of care in the clinical practice.
VytisknoutZobrazeno: 26. 5. 2024 13:21